PMID- 21435216
OWN - NLM
STAT- MEDLINE
DCOM- 20110801
LR  - 20220318
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 11
DP  - 2011 Mar 24
TI  - Safety and treatment patterns of multikinase inhibitors in patients with 
      metastatic renal cell carcinoma at a tertiary oncology center in Italy.
PG  - 105
LID - 10.1186/1471-2407-11-105 [doi]
AB  - BACKGROUND: Multikinase inhibitors (MKIs) sunitinib and sorafenib have become a 
      standard of care for metastatic renal cell carcinoma (mRCC). This study assessed 
      safety and treatment patterns for these agents in a real-world clinical practice 
      setting in Italy. METHODS: A retrospective medical record review was performed at 
      a tertiary oncology center in Italy. The study included MKI-naive non-trial 
      patients >/=18 years old, with a histological diagnosis of mRCC, and who received 
      sunitinib or sorafenib as first MKI during 9/2005-7/2008. Data were collected on 
      adverse events (AEs), treatment modifications (discontinuations, interruptions, 
      dose changes), and reasons for these modifications. RESULTS: 145 patients were 
      included; 85 received sunitinib and 60 received sorafenib as first-line MKI. 
      Median treatment duration was 6.6 (sunitinib) and 5.8 (sorafenib) months. 97.6% 
      and 70.0% of patients receiving sunitinib and sorafenib, respectively, 
      experienced >/=1 AE; 27.1% and 31.7% had >/=1 grade 3/4 AE. The most common any grade 
      AE for sunitinib was fatigue/asthenia (81.2%), followed by mucositis/stomatitis 
      (58.8%) and decreased taste sensation (42.4%), while for sorafenib this was 
      fatigue/asthenia (43.3%) followed by hand-foot syndrome (38.3%) and diarrhea 
      (31.7%). Treatment discontinuation, interruption, and dose reduction due to AEs 
      occurred in 11.8%, 23.5%, and 30.6%, respectively, of patients receiving 
      sunitinib, and 5.0%, 23.3%, and 36.7%, respectively, of patients receiving 
      sorafenib. CONCLUSIONS: In this retrospective study, most patients experienced >/=1 
      AE during first-line MKI treatment. AEs were reported frequently and resulted in 
      treatment modifications in 40% of patients receiving sunitinib and 45% of 
      patients receiving sorafenib. These results suggest a need for additional 
      effective and more tolerable treatments for mRCC.
FAU - Porta, Camillo
AU  - Porta C
AD  - Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Piazzale 
      C, Golgi 19, 27100 Pavia, Italy. c.porta@smatteo.pv.it
FAU - Paglino, Chiara
AU  - Paglino C
FAU - Imarisio, Ilaria
AU  - Imarisio I
FAU - Canipari, Cinzia
AU  - Canipari C
FAU - Chen, Kristina
AU  - Chen K
FAU - Neary, Maureen
AU  - Neary M
FAU - Duh, Mei Sheng
AU  - Duh MS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110324
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Benzenesulfonates)
RN  - 0 (Indoles)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (Pyrroles)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Benzenesulfonates/administration & dosage/adverse effects
MH  - Carcinoma/*drug therapy/pathology/physiopathology
MH  - Fatigue/etiology/prevention & control
MH  - Female
MH  - Humans
MH  - Indoles/administration & dosage/adverse effects
MH  - Italy
MH  - Kidney Neoplasms/*drug therapy/pathology/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Niacinamide/analogs & derivatives
MH  - Oncology Service, Hospital
MH  - Phenylurea Compounds
MH  - Protein Kinase Inhibitors/administration & dosage/adverse effects
MH  - Pyridines/administration & dosage/adverse effects
MH  - Pyrroles/administration & dosage/adverse effects
MH  - Sorafenib
MH  - Sunitinib
MH  - Treatment Outcome
PMC - PMC3079688
EDAT- 2011/03/26 06:00
MHDA- 2011/08/02 06:00
PMCR- 2011/03/24
CRDT- 2011/03/26 06:00
PHST- 2010/06/07 00:00 [received]
PHST- 2011/03/24 00:00 [accepted]
PHST- 2011/03/26 06:00 [entrez]
PHST- 2011/03/26 06:00 [pubmed]
PHST- 2011/08/02 06:00 [medline]
PHST- 2011/03/24 00:00 [pmc-release]
AID - 1471-2407-11-105 [pii]
AID - 10.1186/1471-2407-11-105 [doi]
PST - epublish
SO  - BMC Cancer. 2011 Mar 24;11:105. doi: 10.1186/1471-2407-11-105.